J&J Pulls Yondelis NDA For Ovarian Cancer Ahead Of Final Survival Data Release
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Faced with the prospect of having to run an additional Phase III study to secure FDA approval of its oncologic Yondelis (trabectedin), Johnson & Johnson’s Centocor Ortho Biotech Products division decided to withdraw the NDA and is reviewing the drug’s clinical development program in recurrent ovarian cancer.
You may also be interested in...
Two In One Day: Centocor Ortho Biotech Gets Complete Response Letters For Doxil In Breast Cancer And Yondelis In Ovarian Cancer
For Yondelis, FDA has requested mature overall survival data from an ongoing pivotal trial. For Doxil, it is likely another trial will be necessary.
Surrogate Endpoints Don't Convince ODAC: Panel Votes No On Two Centocor/Ortho Biotech Drugs
ODAC votes 14-1 against Yondelis in combination with Doxil for ovarian cancer, and 13-0 against Doxil in combination with docetaxel for metastatic breast cancer.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.